← Leaderboards
Adam M Sonabend
Northwestern University
$6,275,929
Attributed
$7,398,300
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,398,300 · 4
By mechanism
R01$4,105,629 · 2
DP5$1,985,000 · 1
U19$1,307,671 · 1
Top collaborators
- Roger Stupp5 shared
Most similar at Northwestern University
Same institution · by research overlap
- Harris R Perlman$22,048,932
- Amy Beth Heimberger$11,078,637
- Todd B Parrish$4,304,754
- Matthew Christopher Tate$1,056,334
- Hao F Zhang$15,987,786
Others in their field
Top investigators on “Glioblastoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$50,454,235
- John H Sampson · Duke University$34,869,540
- Walter John Curran · Thomas Jefferson University$27,327,059
- Jann N Sarkaria · Mayo Clinic Coll Of Medicine, Rochester$23,947,143
- Jeremy N Rich · University Of Pittsburgh At Pittsburgh$21,935,828
- Maciej S Lesniak · Northwestern University$18,837,339
Research focus
GlioblastomaRecurrenceTumorPharmaceutical PreparationsGliomaSpecimenOperative Surgical ProceduresCharacteristicsResponseCell LineClinical TrialsNeoplastic CellExhibitsBrainGlioma Cell LineExcisionMolecularBrain NeoplasmsCellsPatient SubsetsImplantBlood - Brain Barrier AnatomyBaseInfiltration
Grant awards (20)
Leveraging doxorubicin immune-modulation, blood-brain barrier opening, and personalized medicine for effective immunotherapy in glioblastoma. A mechanistic approach and pharmacokinetic trial.$269,642
U19 · FY2025 · CA · contact PI
MAPK as target of glioma immunoediting by CD8 T-cells, and predictor of response to immunotherapy$364,720
R01 · FY2024 · NS · contact PI
Blood-brain barrier disruption with implantable ultrasound to enhance paclitaxel delivery: A Phase 1-2 clinical trial in recurrent glioblastoma$337,354
R01 · FY2024 · CA · contact PI
Leveraging doxorubicin immune-modulation, blood-brain barrier opening, and personalized medicine for effective immunotherapy in glioblastoma. A mechanistic approach and pharmacokinetic trial.$256,156
U19 · FY2024 · CA · contact PI
Blood-brain barrier disruption with implantable ultrasound to enhance paclitaxel delivery: A Phase 1-2 clinical trial in recurrent glioblastoma$481,500
R01 · FY2023 · CA · contact PI
MAPK as target of glioma immunoediting by CD8 T-cells, and predictor of response to immunotherapy$376,000
R01 · FY2023 · NS · contact PI
Leveraging doxorubicin immune-modulation, blood-brain barrier opening, and personalized medicine for effective immunotherapy in glioblastoma. A mechanistic approach and pharmacokinetic trial.$264,248
U19 · FY2023 · CA · contact PI
Blood-brain barrier disruption with implantable ultrasound to enhance paclitaxel delivery: A Phase 1-2 clinical trial in recurrent glioblastoma$505,516
R01 · FY2022 · CA · contact PI
MAPK as target of glioma immunoediting by CD8 T-cells, and predictor of response to immunotherapy$376,000
R01 · FY2022 · NS · contact PI
Leveraging doxorubicin immune-modulation, blood-brain barrier opening, and personalized medicine for effective immunotherapy in glioblastoma. A mechanistic approach and pharmacokinetic trial.$264,245
U19 · FY2022 · CA · contact PI
Blood-brain barrier disruption with implantable ultrasound to enhance paclitaxel delivery: A Phase 1-2 clinical trial in recurrent glioblastoma$501,049
R01 · FY2021 · CA · contact PI
MAPK as target of glioma immunoediting by CD8 T-cells, and predictor of response to immunotherapy$372,867
R01 · FY2021 · NS · contact PI
Leveraging doxorubicin immune-modulation, blood-brain barrier opening, and personalized medicine for effective immunotherapy in glioblastoma. A mechanistic approach and pharmacokinetic trial.$253,380
U19 · FY2021 · CA · contact PI
Blood-brain barrier disruption with implantable ultrasound to enhance paclitaxel delivery: A Phase 1-2 clinical trial in recurrent glioblastoma$419,323
R01 · FY2020 · CA · contact PI
MAPK as target of glioma immunoediting by CD8 T-cells, and predictor of response to immunotherapy$371,300
R01 · FY2020 · NS · contact PI
TOP2A effects on transcription in gliomas: implications for personalized therapy$395,000
DP5 · FY2019 · OD · contact PI
TOP2A effects on transcription in gliomas: implications for personalized therapy$395,000
DP5 · FY2018 · OD · contact PI
TOP2A effects on transcription in gliomas: implications for personalized therapy$395,000
DP5 · FY2017 · OD · contact PI
TOP2A effects on transcription in gliomas: implications for personalized therapy$400,000
DP5 · FY2016 · OD · contact PI
TOP2A effects on transcription in gliomas: implications for personalized therapy$400,000
DP5 · FY2015 · OD · contact PI